The stock climbed roughly 10% in premarket trading after closing at $2.96 on Monday.
Pemvidutide led to a decrease of 1.45 heavy-drinking days per week compared to placebo.
The increase lifted 75 million warrants past their $3 exercise threshold.
Altimmune stock gained roughly 10% in premarket trading on Tuesday. The company’s Phase 2 RECLAIM study showed pemvidutide achieved its primary endpoint. U.S. markets had not opened at the time of reporting.
The price action surpassed a key financing level. In April, Altimmune released 75 million warrants that can be exercised immediately. Each warrant is priced at $3 per share.
A complete cash exercise has the potential to generate $225 million in gross proceeds, amounting to 42% of Altimmune’s cash and short-term investments as of April 30. The funds may help cover expenses tied to the anticipated Phase 3 trial in metabolic dysfunction-associated steatohepatitis, or MASH.
The financing will be dilutive. Calculations show the warrant shares represent 38.6% of Altimmune’s basic share count as of May 8. This figure does not account for pre-funded warrants or employee equity awards. The exercise of the warrants is not mandatory.
RECLAIM assigned approximately 100 patients to either pemvidutide or placebo groups. Participants received treatment over 24 weeks. Altimmune shared this efficacy analysis: SEC
Week-24 measure
Placebo
Pemvidutide
Treatment effect
P-value
Weekly reduction in heavy-drinking days
-2.75
-4.20
-1.45 days
0.0014
Reduction by two WHO risk levels
34.8%
64.4%
+29.6 points
0.0049
No heavy-drinking days
17.4%
42.2%
+24.8 points
0.0066
Rise in days without alcohol
20.5%
38.9%
+18.4 points
0.0075
Change in PEth alcohol biomarker
+22.0
-153.4
-175.3
Below 0.0001
Participants in the active group cut heavy drinking by 4.20 days per week, while those receiving placebo reduced their heavy drinking by 2.75 days. The additional reduction of 1.45 days in the active group surpassed the projections of Jefferies Financial Group NYSE:JEF analysts, who anticipated an effect between 0.9 and 1.1 days.
The observed effect surpassed that range by approximately 32% to 61%. Early estimates suggest an annual reduction of about 75 heavy-drinking days, based on the persistence of the 24-week effect. This projection was not an endpoint of the trial.
Additional endpoints reinforced the outcome. Approximately two-thirds of patients receiving treatment saw a two-level reduction in World Health Organization risk scores. Pemvidutide further delivered a 9.1% weight loss compared to placebo.
Thomas Smith, analyst at Leerink Partners, described the initial efficacy results as “encouraging.” He also noted it is still challenging to compare them to Novo Nordisk’s NYSE:NVO semaglutide. Reuters
Pemvidutide was linked to a higher incidence of gastrointestinal side effects. Nausea occurred in 44% of patients given the drug, compared to 24% for those on placebo. Rates of constipation stood at 26% for pemvidutide recipients and 6% for the placebo group.
Five individuals discontinued pemvidutide due to side effects linked to the drug. A single serious incident involving low blood sodium was regarded as potentially connected to treatment. Overall, discontinuations reached 20% for pemvidutide and 22% for placebo.
Altimmune intends to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration. The agency is expected to assist in outlining the registrational pathway. The findings are currently available as topline data and have not yet appeared in a peer-reviewed publication.
Risks are still elevated. RECLAIM was limited in size and included only participants with body mass indexes greater than 25. Placebo group improvements were significant. A more extensive study could reveal reduced effectiveness or new safety concerns. Exercising warrants would further dilute current shareholders.
Investors are set to monitor if Altimmune remains above the $3 mark in regular trading. Continued momentum may increase the appeal of warrant exercises, offering additional funds ahead of upcoming Phase 3 expenditures and resulting in a higher share count.
What is driving Altimmune shares higher ahead of Tuesday’s opening bell?
Premarket quotes most recently showed $2.96, representing a rise of roughly 7%. Previously, Reuters tracked gains at close to 10%, highlighting the volatility in premarket activity. Positive Phase 2 RECLAIM study results in alcohol use disorder drove the movement. Additionally, shares hovered just under the company’s $3 warrant exercise price.
What level of strength did RECLAIM's main efficacy outcome demonstrate?
Pemvidutide lowered weekly heavy-drinking days by 4.20 from baseline, compared to a 2.75-day decrease for placebo, resulting in a 1.45-day difference between treatments. The outcome showed a p-value of 0.0014. Jefferies had projected a placebo-adjusted improvement ranging from 0.9 to 1.1 days. The result surpassed that widely cited estimate.
Did pemvidutide achieve success on secondary endpoints considered significant by the FDA?
A reduction of two levels on the WHO drinking-risk scale was observed in 64.4% of patients given the treatment, compared to 34.8% for placebo, with a p-value of 0.0049. The proportion of participants with zero heavy-drinking days during weeks 21 to 24 reached 42.2% with treatment, versus 17.4% on placebo, and a p-value of 0.0066. Altimmune stated that both outcomes are recognized as FDA registrational endpoints.
Was pemvidutide’s safety record sufficiently clear to proceed to larger trials?
Most adverse events were mild or moderate, with gastrointestinal issues frequently reported. Nausea occurred in 44% of patients on pemvidutide and 24% receiving placebo. Discontinuations due to drug-related reasons were 10%, while overall discontinuation rates were 20% for pemvidutide and 22% for placebo. There was one serious case of hyponatremia considered possibly linked to treatment. Broader studies are needed to determine if these rates are sustainable.
Might the improvement in drinking be solely linked to the weight-loss from pemvidutide?
Pemvidutide resulted in a 9.1% weight loss compared to placebo after 24 weeks. Measures of drinking behavior and the PEth alcohol biomarker also saw significant gains. Altimmune did not separate the impact of weight loss from that of reduced craving, leaving the primary mechanism for the benefit unclear in this topline update. Complete findings are still pending peer review.
What are the upcoming steps involving the FDA and the AUD program?
Altimmune intends to seek an end-of-Phase 2 meeting with the FDA. No Phase 3 AUD timeline, trial enrollment, or number of necessary studies has been detailed. The agency’s input is expected to inform endpoints, dosage determination, and the overall registrational approach. Altimmune is also preparing for a medical conference presentation and submission to a peer-reviewed journal. The regulatory route remains unclear.
How does Altimmune’s market value stack up against its available cash?
With shares priced at $2.96 and 194.5 million outstanding in May, Altimmune’s basic equity value is near $576 million. In addition, 10.75 million pre-funded warrants act as further common-share equivalents. As of April 30, Altimmune held $535 million in cash and investments. The company’s term debt stood at around $35 million at the end of March. These figures do not account for subsequent expenditures and are approximate.
What is the impact of the $3 warrant and dilution overhang?
In April, 75 million warrants were issued, each with a $3 exercise price. These represent roughly 38.6% of the number of common shares as of May. If all warrants are exercised for cash, the company would raise $225 million and the share count would increase by 75 million. The strike price is just above the most recent $2.96 premarket level. This arrangement could affect trading dynamics, though exercise is not mandatory.
Which key milestones are upcoming in Altimmune’s pipeline?
Altimmune is set to initiate the PERFORMA Phase 3 trial in MASH in the third quarter of 2026, aiming for a 52-week interim analysis in 2029. Enrollment for the RESTORE Phase 2 trial in alcohol-associated liver disease is expected to complete this quarter. This study, involving around 100 patients, will last for 48 weeks, with data projected for release in 2027. Market attention is also on FDA guidance and the publication of detailed RECLAIM results.
Jerzy Lewandowski is a senior markets editor at TS2.tech. His coverage ranges from stocks and semiconductors to AI and the broader global markets. He studied economics at the University of Warsaw and worked in investment analysis before becoming a financial journalist. Follow Jerzy Lewandowski on Google News.
A figure above or below the 12.0 consensus could impact Treasury yields, the dollar, and cyclical stocks by influencing short-term growth outlooks.
#2
NAHB Housing Sentiment
A reading above or below 33 will influence expectations for housing demand, mortgage rate trends, and homebuilder stocks.
#3
Fabrinet After the Close
Investors are focusing on revenue, margins, and comments on datacom as key factors for companies involved in optical networking and AI infrastructure supply chains.
